Phoremost logo


Advances in genomics and basic research are providing a long list of clear causes that lie at the heart of a range of debilitating diseases. This has the potential to open the door to many new and improved targeted therapies. However, many of these newly characterized disease targets are intractable to current drug discovery technologies.  PhoreMost is aiming to remove these barriers to new drug development with its novel SITESEEKER technology, a live-cell phenotypic assay system that can rapidly identify unexpected, or “cryptic” druggable sites in specific disease driving targets and pathways that can’t be readily seen using conventional non-cell based analytical methods.


At the heart of the SITESEEKER® platform is the use of live-cells to probe the full-complexity of nature for unexpected points of therapeutic intervention.  Uncovering these nodes of disease-relevance, and how small-molecule drugs can be designed rapidly to them, is achieved using a diverse (109) library of exogenously delivered small 3-dimensional protein-fragment shapes, which interact on a genome-wide scale with host-cell proteins to describe new druggable space that is intimately linked to disease causation. This process, called Protein Interference (PROTEINi), lies at the heart of the SITESEEKER platform and differs fundamentally from other genome-based target screening technologies, such as RNAi and CRISPR, in operating directly at the protein level, so that new druggable space can be defined as an inherent part of the target-function screening process.